Basic Research Support for the CCR

CCR的基础研究支持

• 批准号: 9154307
• 负责人: Robert Wiltrout
• 金额: $ 91.76万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9154307
• 关键词: Acquired Immunodeficiency Syndrome; Animal Technicians; Apoptotic; Area; Autoimmune Diseases; Basic Science; Biological Assay; Biomedical Research; Cancer Research Project; Cell Death; Cell Lineage; Cell Survival; Cell physiology; Clinical; Communicable Diseases; Dendritic Cells; Development; Disease; Effector Cell; Genetic; HIV; HLA Antigens; Human Resources; Immune response; Immunity; Immunobiology; Immunogenetics; Immunotherapy; Inflammation; Information Technology; Interleukin-7; Laboratories; Laboratory Animals; Laboratory Research; MHC Class II Genes; Malignant Neoplasms; Molecular Biology; Molecular Models; Molecular Target; Mus; NCI Center for Cancer Research; Natural Products Chemistry; Predisposition; Protein Chemistry; Qualifying; Renal carcinoma; Research; Research Support; Resistance; Role; Scientist; Susceptibility Gene; T-Lymphocyte and Natural Killer Cell; Technical Expertise; Urologic Oncology; Vaccines; anticancer research; base; cancer genetics; cancer therapy; carcinogenesis; cell type; cellular imaging; cytokine; member; molecular modeling; multidisciplinary; novel; programs; screening; targeted cancer therapy; tumor

The Basic Research Program (BRP) provides scientific and technical expertise to NCI's Center for Cancer Research (CCR) in areas ranging from cancer and human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), to the basic cellular processes underlying cancer, infectious diseases, and autoimmune disorders. Research topics supported by the BRP include: -Investigating ways in which novel, molecularly targeted cancer therapies can be used alone or in combination with immunotherapy in various tumor models (Molecular Immunotherapy Section, Cancer and Inflammation Program). -Understanding the genetic basis for resistance or susceptibility to disease conferred by human leukocyte antigen (HLA) class I and class II genes, which have a central role in the innate immune response (HLA Immunogenetics Section, Cancer and Inflammation Program). -Investigating the role of cytokines such as interleukin-7 (IL-7) in the development of T lymphocyte and natural killer (NK) cell lineages and their role in promoting cell survival, terminal differentiation, and apoptotic cell death (Cytokines and Immunity Section, Cancer and Inflammation Program). -Examining the role of dendritic cells, other innate or adaptive effector cell types, and proinflammatory or immunoregulatory cytokines on carcinogenesis and cancer therapy (Cancer Immunobiology Section, Cancer and Inflammation Program). -Support in bioassay development and screening, natural products chemistry, protein chemistry, molecular biology, and high-content cellular imaging to facilitate multidisciplinary, molecular targets discovery research (Molecular Targets Laboratory). -Discovery and characterization of renal carcinoma susceptibility genes (Urologic Oncology Research Group, Urologic Oncology Branch).

基础研究计划（BRP）为NCI的癌症研究中心（CCR）提供科学和技术专业知识，范围从癌症和人类免疫缺陷病毒（HIV）/获得性免疫缺陷综合征（AIDS）到癌症，传染病和自身免疫性疾病的基本细胞过程。BRP支持的研究主题包括：-研究新的分子靶向癌症疗法可以单独使用或与免疫疗法联合用于各种肿瘤模型的方法（分子免疫疗法部分，癌症和炎症计划）。- 了解人类白细胞抗原（HLA）I类和II类基因赋予的对疾病的抗性或易感性的遗传基础，这些基因在先天免疫应答中起核心作用（HLA免疫遗传学部分，癌症和炎症计划）。- 研究细胞因子如白细胞介素-7（IL-7）在T淋巴细胞和自然杀伤（NK）细胞谱系发育中的作用及其在促进细胞存活、终末分化和凋亡性细胞死亡中的作用（细胞因子和免疫部分，癌症和炎症计划）。- 检查树突状细胞、其他先天或适应性效应细胞类型和促炎或免疫调节细胞因子对致癌和癌症治疗的作用（癌症免疫生物学部分，癌症和炎症计划）。- 支持生物测定开发和筛选、天然产物化学、蛋白质化学、分子生物学和高含量细胞成像，以促进多学科分子靶点发现研究（分子靶点实验室）。- 肾癌易感基因的发现和表征（泌尿肿瘤学研究组，泌尿肿瘤学分支）。